73 stories
BPC-157 is a synthetic 15-amino-acid fragment derived from a gastric protein. It became one of the most-requested research peptides in the wellness and longevity market on the strength of preclinical data showing accelerated tendon, ligament, and gut tissue repair. Most of that work sits in rodent or in-vitro studies rather than in human trials.
The regulatory picture shifted decisively on July 23, 2026. The FDA Pharmacy Compounding Advisory Committee (PCAC) voted 8-6 with 1 abstention to recommend adding BPC-157 to the Section 503A bulks list, overriding the June 29-30 FDA career-staff briefing documents that recommended against it. The vote is advisory; formal rulemaking would take approximately 6-18 months before compounding pharmacies could legally prepare BPC-157 under the 503A framework. Prior to the PCAC vote, BPC-157 sat in Category 2 (insufficient information to evaluate) and was the subject of DOJ action, state medical-board enforcement against clinics, and UK MHRA notices.
The clinical evidence base remains thin. A 2026 STAT and Undark investigation sharpened the point: nearly all of the roughly 200 BPC-157 studies on PubMed list Croatian researcher Predrag Sikiric or a close colleague as an author, the work carries undisclosed patent and commercial conflicts, and only three human studies have been published. Stories here cover new preclinical work, regulatory action, and any movement toward registered human trials. See [[pcac]] and [[peptide-compounding]] for adjacent threads.
Combining multiple peptides like GHK-Cu, BPC-157, and TB-500 is becoming a growing trend, especially among GLP-1 medication users dealing with skin laxity from rapid weight loss. Goop feature explores risks and benefits with dermatologist input.
The UK's MHRA is investigating peptide clinics promoting BPC-157, MOTS-C, and Cortexin with unproven claims. Making medicinal claims classifies these products as medicines under UK law.
Physician-journalist Dhruv Khullar traces the peptide movement from CrossFit communities to mainstream wellness, documenting contamination (lead in BPC-157, endotoxins in TB-500), lack of human trials, and RFK Jr.'s attacks on FDA restrictions.
CBC investigation compares the peptide trend to historical pseudoscience, with scientists emphasizing no large-scale human trials exist for peptides sold by influencers.
The MHRA is investigating whether UK peptide clinics are breaking the law by making medicinal claims for unregulated peptides like BPC-157 and Thymosin Alpha. Clinics were found charging £350–£450/month per peptide despite labeling them "research only."
The regulated peptide market is worth $50 billion and projected to double by the early 2030s. Unregulated peptides like BPC-157 and TB-500 lack rigorous human safety data and are increasingly sourced from gray-market Chinese distributors.
Comprehensive look at peptide therapies from approved GLP-1s to unregulated substances like BPC-157 and TB-500. Most evidence comes from animal studies, with benefits "largely unvalidated in human trials."
A physician essays about a patient who stopped her statin despite high coronary calcium yet continues injecting BPC-157 ordered online, highlighting the growing trust gap between consumer-hyped peptides and evidence-backed medications.
A research review characterizes TB-500 and BPC-157 as distinct informational modulators, with TB-500 linked to thymosin beta-4 biology and BPC-157 acting as a localized signaling stabilizer.
The FDA is moving to allow compounding pharmacies to produce 14+ injectable peptides banned in 2023. Health Secretary RFK Jr. publicly backed the reversal, while top FDA leaders reportedly have reservations about politically-driven decisions.
Longevity enthusiasts anticipate FDA loosening restrictions on BPC-157, ipamorelin, and MOTs-C. Industry notes it may take months for compounding pharmacies to ramp up supply after reclassification.
Investigation into the unregulated peptide market noting how easily BPC-157 can be purchased online with next-day delivery, amid celebrity endorsements from Joe Rogan and growing safety concerns.
Analyzes the announcement that ~14 of 19 peptides on FDA's Category 2 list will move back to Category 1, restoring access through licensed compounding pharmacies with a prescription.
London Standard investigation exposes consumers self-injecting BPC-157 and CJC-1295 sourced from Discord groups and online sellers, bypassing medical oversight. UK solicitors warn clinics are on 'very shaky ground.'
Updated explainer clarifying BPC-157 is not outright banned but in Category 2 requiring further investigation. Discusses potential shifts after public statements about moving peptides back to Category 1.
Physician William Meller describes treating a patient in anaphylaxis after self-injecting online peptides, and critiques RFK Jr.'s plan to move ~14 compounds off the FDA restricted list.
Investigation into men injecting BPC-157 and Thymosin Alpha-1 from unregulated internet suppliers. Doctors warn of severe allergic reactions and potential cancer risk from growth-pathway compounds.
Health Secretary Kennedy announced on Joe Rogan's podcast that the FDA will soon reclassify about 14 peptides currently restricted from compounding pharmacies, aiming to curb gray-market sourcing.